Conclusion
The study of T2D-TB comorbidity from the immunoendocrine point of view is of utmost importance to understand the background of this binomial, as well as to propose better strategies for the control of this comorbidity. Active GCs represent a negative factor in the development of both entities, with a negative effect on glucose metabolism and the development of a non-protective immune response. Treatment with BEA represents a novel strategy as an adjuvant in the treatment of TB alone and comorbidity with T2D. For these reasons, it is of utmost importance to continue with the study of the BEA through its escalation to clinical studies to be used in patients.